5134W-11 Cushing's LAR. CSOM230G2304

Cushing's LAR. CSOM230G2304

Type of Study
Neuroscience - Pituitary
Short Description

To assess the efficacy of two Pasireotide LAR regimens (starting doses of 10 mg and 30 mg followed by uptitration if needed or continuation of the same dose) independently in patients with Cushing’s disease after 7 months of treatment regardless of up titration at Month 4.

Status
Open
Principal Investigator
William H. Ludlam, MD
Eligibility Notes

Inclusion:

  • Diagnosis of ACTH-dependant Cushing’s disease
  • Male or female patients aged 18 years or greater


Exclusion:

  • Candidates for surgical treatment at the time of study entry
  • Received pituitary irradiation within the last ten years
  • Any previous pasireotide treatment
  • Treated with mitotane during the last 6 months
Contact Name
Jeannie Steed
Phone
206-386-3878
Email
jeannie.steed@swedish.org